| Test Group (n = 188) | Control Group (n = 181) | #p-value | ||||||
---|---|---|---|---|---|---|---|---|---|
Baseline (T0) | 1st Follow-up (T1) | 2nd Follow-up (T2) | Baseline (T0) | 1st Follow-up (T1) | 2nd Follow-up (T2) | Time | Time *Group | Group | |
Healthy Perio-conditions (n, %) | 4 (2.2%) | 10 (5.3%) | 33 (17.6%) | 4 (2.2%) | 9 (5.0%) | 12 (6.6%) | Â | Â | Â |
VPI (mean ± SD)(0 ~ 1) § | 0.19 ± 0.16a | 0.14 ± 0.13b | 0.15 ± 0.14b | 0.19 ± 0.15a | 0.16 ± 0.16b | 0.22 ± 0.17a |  <0.001 |  <0.001 |  0.025 |
 VPI > 0 (n,%) | 157 (83.5%) | 138 (73.4%) | 141 (75.0%) | 149 (82.3%) | 130 (71.8%) | 151 (73.4%) |  |  |  |
 VPI > 0.5 (n,%) | 7 (3.7%) | 1 (0.5%) | 0 (0%) | 4 (2.2%) | 4 (2.2%) | 9 (5%) |  |  |  |
BOP% (mean + SD)(0 ~ 100%) § | 57 ± 27a | 46 ± 30b | 35 ± 29c | 58 ± 27a | 52 ± 29b | 46 ± 26c | < 0.001 | 0.001 | 0.014 |
 BOP> 0 (n,%) | 181 (96.3%) | 166 (88.3%) | 151 (75.0%) | 168 (92.8%) | 164 (90.6%) | 151 (83.4%) |  |  |  |
 BOP> 50% (n,%) | 103 (54.8%) | 71 (37.8%) | 48 (25.5%) | 101 (55.8%) | 84 (46.4%) | 64 (35.4%) |  |  |  |
NPoc (mean + SD)(0 ~ 6) ¶ | 0.22 ± 0.25a | 0.29 ± 0.19b | 0.08 ± 0.16c | 0.21 ± 0.25a | 0.30 ± 0.16b | 0.09 ± 0.17c | < 0.001 | 0.293 | 0.402 |
 0-3 mm (n,%) | 165 (87.8%) | 162 (86.2%) | 179 (95.2%) | 165 (91.2%) | 143 (79.0%) | 172 (95.0%) |  |  |  |
  > 3 mm (n,%) | 23 (12.2%) | 26 (13.8%) | 9 (4.8%) | 16 (8.8%) | 38 (21.0%) | 9 (5.0%) |  |  |  |
NLoA (mean + SD)(0 ~ 6) ¶ | 0.23 ± 0.24a | 0.22 ± 0.18a | 0.12 ± 0.16b | 0.21 ± 0.15a | 0.21 ± 0.16a | 0.10 ± 0.17b | < 0.001 | 0.445 | 0.352 |
 0-3 mm (n,%) | 167 (88.8%) | 168 (89.4%) | 179 (95.2%) | 165 (91.2%) | 154 (85.1%) | 172 (95.0%) |  |  |  |
  > 3 mm (n,%) | 21 (11.2%) | 20 (10.6%) | 9 (4.8%) | 16 (8.8%) | 27 (14.9%) | 9 (5.0%) |  |  |  |